TIMP-1 and CD82 expression status in patients with pancreatic ductal adenocarcinoma (PDAC) might demonstrate future usefulness as a differentiation marker and give us new insight into tumorigenic metastatic potential. This evidence concerns the gene TIMP1 and pancreatic ductal adenocarcinoma.